Glioblastoma (Glioblastoma Multiforme)

A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Also Known As:
Glioblastoma Multiforme; Grade IV Astrocytoma; Astrocytomas, Grade IV; Giant Cell Glioblastomas; Glioblastoma, Giant Cell; Glioblastomas; Glioblastomas, Giant Cell; Grade IV Astrocytomas; Astrocytoma, Grade IV; Giant Cell Glioblastoma
Networked: 11830 relevant articles (637 outcomes, 2047 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Glioma (Gliomas)
3. Astrocytoma (Pilocytic Astrocytoma)
4. Glioblastoma (Glioblastoma Multiforme)
5. Brain Neoplasms (Brain Tumor)


1. Weller, Michael: 111 articles (12/2015 - 01/2002)
2. Reardon, David A: 74 articles (10/2015 - 04/2003)
3. Wen, Patrick Y: 74 articles (10/2015 - 02/2006)
4. Wick, Wolfgang: 72 articles (11/2015 - 09/2002)
5. Stupp, Roger: 58 articles (12/2015 - 03/2002)
6. Cloughesy, Timothy F: 58 articles (12/2015 - 09/2002)
7. Bigner, Darell D: 56 articles (06/2015 - 01/2004)
8. Chang, Susan M: 55 articles (12/2015 - 05/2002)
9. Mischel, Paul S: 55 articles (10/2015 - 09/2002)
10. Prados, Michael D: 55 articles (08/2015 - 10/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Glioblastoma:
1. temozolomide (Temodar)FDA LinkGeneric
2. bevacizumabFDA Link
07/01/2014 - "This recommendation applies to adult patients with progressive glioblastoma Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. "
06/01/2013 - "Bevacizumab monotherapy has proven effective for recurrent glioblastoma, and it extended progression-free survival and improved patient quality of life in various clinical trials. "
11/01/2015 - "Two large phase III trials, RTOG 0825 and AVAglio, failed to demonstrate an overall survival benefit from antiangiogenic therapy with bevacizumab added to combined chemoradiotherapy (TMZ) in patients with newly diagnosed glioblastoma, but a trend toward improved survival with increasing age can be noted. "
11/01/2012 - "Based on promising results from clinical trials that bevacizumab can prolong progression-free survival in recurrent glioblastoma patients, the US FDA granted this drug accelerated approval for the treatment of recurrent or progressive glioblastoma; however, there has been no evidence that the overall median survival of patients is prolonged. "
08/01/2012 - "Recently published single-arm evaluations of adding bevacizumab to standard first-line therapy in glioblastoma multiforme have shown an improvement in progression-free survival and overall survival when compared with historical controls obtained prior to widespread use of bevacizumab in recurrent glioblastoma multiforme. "
3. irinotecan (Camptosar)FDA LinkGeneric
4. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
5. Carmustine (FIVB)FDA Link
6. DNA (Deoxyribonucleic Acid)IBA
7. Epidermal Growth Factor Receptor (EGF Receptor)IBA
8. Paclitaxel (Taxol)FDA LinkGeneric
9. Carboplatin (JM8)FDA LinkGeneric
10. Phosphotransferases (Kinase)IBA

Therapies and Procedures

1. Radiotherapy
2. Drug Therapy (Chemotherapy)
3. Heterologous Transplantation (Xenotransplantation)
4. Immunotherapy
5. Boron Neutron Capture Therapy